The weight loss drugs related to GLP-1 have become a stimulant in pharmaceutical units.
On October 13, the "slimming god medicine" concept stock Borey Pharmaceutical (688166.SH) rose as much as 20%.
One of the reasons for the sharp rise in share prices may point to an online summary of the meeting.
Yuan Jiandong, chairman of Bouri Pharmaceuticals, pointed out on an investor conference call on October 12 that he personally tested the drug (BGM0504 injection) and his weight dropped from 91 kg to 76 kg.
"I'm not that worried about security. Well, I said I made my own medicine and I tried it myself. I also tried it, but the effect was good. I played for about two months and then dropped from 91 kilograms to 76 kilograms, and the effect is still very obvious. " Yuan Jiandong pointed out.
However, BGM0504 injection is not yet on the market.
It is understood that, as a double agonist of GLP-1/GIP receptor, the two indications of BGM0504 injection for weight loss and the treatment of type 2 diabetes are only ethical approvals in phase 2 clinical trials, of which phase 2 clinical treatment of type 2 diabetes has begun to enter the group.
According to media reports, Borey did not deny the fact that the chairman personally tested the drug.
"individual conditions do not represent clinical trial data." The customs staff of Borey Pharmaceutical responded.
On the afternoon of October 13th, ID:TradeWind01 called Borey Pharmaceutical and Securities Department several times to verify the authenticity of the news and whether the behavior was suspected of violating the rules, but the phone could not be reached.
However, ID:TradeWind01 noted that by the evening of October 12, Burr Pharmaceutical had publicly disclosed the Investor Research report from October 10 to October 12, 2023 (hereinafter referred to as the "report"), which was basically consistent with the minutes of the online meeting, but key information such as Yuan Jiandong's drug test effect and clinical data of BGM0504 injection did not appear in it.
This means that there is a difference between the contents of the letter approval and the actual minutes.
For example, according to the minutes of the meeting posted online, Bouri expects BGM0504 injection to disclose the results of hypoglycemic indications in the second quarter of 2024 and weight loss in the third and fourth quarters of 24 years.
However, none of the above appeared in the report disclosed on the evening of October 12.
This letter and approval operation is causing controversy among investors.
"the fact that pharmaceutical company executives try popular clinical drugs and actual results is obviously easy to have an impact on market expectations and the company's stock price." A pharmaceutical industry analyst pointed out, "but obviously this matter has not been implemented in the formal letter approval process."
"it is clear that the reasonableness of releasing this information in this way is open to question as to whether the drug was used, how much it was used, and who is responsible for the authenticity and procedure of the matter." The person further pointed out. "for pharmaceutical companies, efficacy information is sensitive, even if it is not the company's financial information, to a certain extent, there is the suspicion of non-standard information disclosure."
